AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT05692180
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Phase 3
Active, not recruiting
- Conditions
- NSCLC
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1350
- Registration Number
- NCT05687266
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Evusheld Japan PMS_Japan Post-Marketing Surveillance (PMS)
Completed
- Conditions
- SARS-CoV-2 Infection
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 366
- Registration Number
- NCT05687877
- Locations
- 🇯🇵
Research Site, Tottori, Japan
MEDI5752 in Japanese Patients With Advanced Solid Tumors.
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT05685472
- Locations
- 🇯🇵
Research Site, Kashiwa, Japan
A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.
Active, not recruiting
- Conditions
- Small Cell Lung Carcinoma
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 254
- Registration Number
- NCT05683977
- Locations
- 🇫🇷
Research Site, Évreux, France
A Study for Observing Severe Asthma in Patients Treated With Tezepelumab
Recruiting
- Conditions
- Asthma
- Interventions
- Other: None (Observational Study)
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 550
- Registration Number
- NCT05677139
- Locations
- 🇨🇭
Research Site, Sion, Switzerland
LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)
Active, not recruiting
- Conditions
- Breast Cancer
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 61
- Registration Number
- NCT05677308
- Locations
- 🇯🇵
Research Site, Yamanashi, Japan
A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants
Phase 1
Terminated
- Conditions
- Non-alcoholic Steatohepatitis
- Interventions
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 31
- Registration Number
- NCT05668936
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study
Recruiting
- Conditions
- Unresectable Hepatocellular Carcinoma
- First Posted Date
- 2022-12-28
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 300
- Registration Number
- NCT05667064
- Locations
- 🇯🇵
Research Site, Yamanashi, Japan
eVusheld Assessment reaL wORld Effectiveness at UPMC
- First Posted Date
- 2022-12-28
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4232
- Registration Number
- NCT05667116
- Locations
- 🇺🇸
Research Site, Pittsburgh, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath